Scientific publications
Helper-dependent adenoviral liver gene therapy protects against induced attacks and corrects protein folding stress in acute intermittent porphyria mice
Carmen Unzu 1, Ana Sampedro, Itsaso Mauleón, Manuela González-Aparicio, Rafael Enríquez de Salamanca, Jesús Prieto, Tomás Aragón, Antonio Fontanellas
Abstract
Acute intermittent porphyria (AIP) is a hepatic metabolic disease that results from haplo-insufficient activity of porphobilinogen deaminase (PBGD). The dominant clinical feature is acute intermittent attacks when hepatic heme synthesis is activated by endocrine or exogenous factors. Gene therapy vectors over-expressing PBGD protein in the liver offers potential as a cure for AIP. Here, we developed a helper-dependent adenovirus (HDA) encoding human PBGD (hPBGD) and assessed its therapeutic efficacy in a murine model of AIP. Intravenous or intrahepatic administration of HDA-hPBGD to AIP mice resulted in a sustained hepatic hPBGD expression in a dose-dependent manner. Intrahepatic administration conveyed full protection against induced porphyria attacks at a significantly lower viral dose than intravenous injection. Transgenic hPBGD accumulated only in the cytosol of hepatocytes as the endogenous protein. Characterization of PBGD-deficient mouse strains revealed that a strong PBGD deficiency causes the chronic disturbance of cytosolic and endoplasmic reticulum folding machineries. This disturbance was completely restored over time by the over-expression of hPBGD. HDA-hPBGD is a promising vector that protects against porphyria attacks and resolves the chronic folding stress associated with low levels of PBGD activity.
CITA DEL ARTÍCULO Hum Mol Genet. 2013 Jul 15;22(14):2929-40. doi: 10.1093/hmg/ddt148. Epub 2013 Apr 5.
![](/.resources/ModuloCUN/resources/img/publicaciones/icono-destacado-investigadores.png)
Our authors
![Ana Sampedro. Programa Hepatología. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-verticales/hepatologia/ana-sampedro-pascual/jcr:content/ana-sampedro-pascual.jpg)
![Itsaso Mauleón. Programa Terapia Génica. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-transversales/terapia-genica/itsaso-mauleon-mayora/jcr:content/mauleon-itsaso.jpg)
![Manuela González. Programa Terapia Génica. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-transversales/terapia-genica/manuela-gonzalez-aparicio/jcr:content/manuela-gonzalez-aparicio.jpg)
![Tomás Aragón. Programa Terapia Génica. Cima](/.imaging/mte/cima/profesional_carrusel-80x80/dam/cima/imagenes/profesionales/programas-transversales/terapia-genica/tomas-aragon-armendariz/jcr:content/tomas-aragon-armendariz.jpg)